Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlighted positive developments such as a strategic collaboration with Astellas and promising Phase I data for VIR-5500, which are strong catalysts. Financials showed controlled expenses and a healthy cash position, despite a slight increase in net loss. The Q&A revealed optimism in pipeline advancements and competitive positioning, despite some management evasiveness. The market cap suggests moderate sensitivity to news, supporting a positive outlook.
Key Financial Performance
R&D Expense $108.9 million for Q1 2026, a decrease from $118.6 million in Q1 2025. The decrease was primarily driven by a $30 million payment to Alnylam in Q1 2025, partially offset by hepatitis delta qualification batch manufacturing costs and higher clinical expenses in Q1 2026.
SG&A Expense $23.3 million for Q1 2026, a slight decrease from $23.9 million in Q1 2025. The decrease was attributed to lower stock-based compensation expense.
Operating Expenses $132.3 million for Q1 2026, a $10.3 million decrease compared to Q1 2025. This was driven by reductions in R&D and SG&A expenses.
Net Loss $125.7 million for Q1 2026, compared to $121 million in Q1 2025. The increase in net loss was due to lower operating expenses being offset by other financial factors.
Cash Position $809.3 million as of March 31, 2026, not including $315 million in proceeds from the Astellas collaboration that closed after the quarter ended.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VIR-5500: Collaboration with Astellas valued at up to $1.7 billion. Phase I data showed favorable safety and tolerability with no dose-limiting toxicities. Demonstrated potential for outpatient administration and significant clinical and commercial advantages. Phase III program initiation planned for 2027.
VIR-5818: Preliminary response data expected in the second half of 2026. Focused on HER2-expressing tumor types.
VIR-5525: Phase I study progressing, targeting EGFR-expressing tumor types like non-small cell lung cancer and colorectal cancer.
Hepatitis Delta Program: Targeting approximately 180,000 patients in the U.S., U.K., and EU. Collaboration with Norgine for commercialization in Europe, Australia, and New Zealand. Monthly dosing regimen offers competitive advantage over daily or weekly alternatives.
Financial Position: Ended Q1 2026 with $809.3 million in cash, cash equivalents, and investments. Additional $315 million from Astellas collaboration post-Q1. Cash runway extended into the second half of 2028.
R&D and SG&A Expenses: R&D expenses decreased to $108.9 million in Q1 2026 from $118.6 million in Q1 2025. SG&A expenses slightly decreased to $23.3 million in Q1 2026 from $23.9 million in Q1 2025.
Astellas Collaboration: Provides immediate capital and reduces near-term development spend while preserving long-term economic upside. Includes $75 million equity investment and $240 million upfront payment.
Norgine Collaboration: Exclusive license for commercialization of hepatitis delta regimen in Europe, Australia, and New Zealand.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Development Risks: The collaboration with Astellas involves substantial risks and uncertainties, including potential delays or failures in clinical development programs, regulatory approvals, and achieving milestones. The success of VIR-5500 and other programs depends on favorable regulatory outcomes and clinical trial results.
Financial Risks: The company reported a net loss of $125.7 million for Q1 2026 and relies heavily on collaborations and equity offerings for funding. There is a risk of insufficient capital to sustain operations and fund development programs beyond the projected cash runway into the second half of 2028.
Market and Competitive Risks: The prostate cancer and hepatitis delta markets are highly competitive. VIR-5500 and the hepatitis delta regimen face competition from existing and emerging therapies, including radioligand therapies and bulevirtide. Success depends on demonstrating superior efficacy, safety, and convenience.
Operational Risks: The company is undertaking multiple clinical programs simultaneously, including the ECLIPSE studies and T-cell engager programs. This increases the complexity of operations and the risk of delays or resource constraints impacting execution.
Supply Chain and Manufacturing Risks: The development and commercialization of VIR-5500 and hepatitis delta therapies require efficient manufacturing and supply chain operations. Any disruptions or inefficiencies could delay clinical trials or product launches.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Prostate Cancer Program (VIR-5500): Vir Biotechnology plans to initiate a registrational Phase III program for VIR-5500 in 2027. The company is advancing its Phase I dose expansion cohort for VIR-5500 in late-line metastatic castration-resistant prostate cancer (MCRPC) patients and anticipates dosing the first patient in combination dose expansion cohorts in early-line MCRPC and metastatic hormone-sensitive prostate cancer over the coming months. The company believes VIR-5500 has the potential to be a best-in-class T-cell engager and aims to position it across the prostate cancer continuum.
Hepatitis Delta Program: Vir Biotechnology expects to report top-line data from the ECLIPSE-1 study in Q4 2026. The company is progressing with its ECLIPSE-2 and ECLIPSE-3 studies, with enrollment on track. The hepatitis delta regimen, combining tobevibart and elebsiran, is designed for monthly subcutaneous dosing and has shown potential best-in-class efficacy with a strong safety profile. The company anticipates presenting complete 96-week Phase II SOLSTICE data at the EASL 2026 Annual Meeting.
HER2-Targeted T-Cell Engager (VIR-5818): Preliminary response data for VIR-5818 monotherapy and combination therapy with pembrolizumab is expected in the second half of 2026. This data will inform dose selection and identify HER2-expressing populations for further study.
EGFR-Targeted T-Cell Engager (VIR-5525): Phase I study enrollment for VIR-5525 is progressing as expected, evaluating both monotherapy and combination therapy with pembrolizumab across multiple EGFR-expressing tumor types.
Financial Guidance: Vir Biotechnology expects its cash runway to extend into the second half of 2028, supported by recent collaborations and financing activities. The company plans to prioritize investments in programs with the greatest potential for patient benefit and value creation.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the level of interest in future development of 5818 in HER2-positive breast cancer?
A:Data on 5818 programs will be shared in the second half of the year, including monotherapy dose escalation and combination with pembrolizumab. Future development will be guided by this data. The bar for HER2-positive breast cancer is high, but there is potential for better treatments.
Q:What is the framework and timeline for potential development of 5500 in earlier treatment settings?
A:A dose escalation for early line 5500 combined with an ARPI is ongoing. Expansion cohorts in combination with enzalutamide are expected in the coming months.
Q:What would constitute a clear signal to initiate Phase III for 5500 late-line MCRPC monotherapy expansion cohort?
A:The decision will be based on the totality of data, including PSA, RECIST, and RPFS. The goal is to start pivotal trials in 2027, pending data.
Q:How tumor-specific is the protease activation profile for PRO-XTEN cleavage across different tumor types?
A:The protease cleavable linker is promiscuous and ensures success across a broad set of tumor types.
Q:What are the latest thoughts on pricing for the pivotal hep B data?
A:Pricing is expected to range between $150,000 and $250,000, based on comparisons to bulevirtide pricing in Europe and Canada, and the severity of the orphan disease.
Q:Is there a minimum durability threshold for 5500 in the late-line castrate-resistant setting before moving to Phase III?
A:There is no specific threshold. Durability will be assessed based on the totality of data, including case examples of patients with confirmed partial responses and long treatment durations.
Q:What are the thoughts on the competitive landscape for HDV and EGFR T-cell engagers?
A:For HDV, the focus is on viral elimination, where the company believes it has superior data compared to competitors. For EGFR T-cell engagers, confidence lies in the differentiation of their masking technology, which allows higher dosing and potentially better therapeutic index.
Q:What data will be disclosed for 5818 in the second half of the year?
A:Data will include monotherapy dose escalation and combination with pembrolizumab. The trial is a basket trial with a variety of tumor types, and results will guide future expansion cohorts.
Q:How many HDV patients in the U.S. and Europe are diagnosed and under care?
A:Out of 174,000 HDV patients, about 61,000 are actively viremic in the U.S., but only 10-15% are diagnosed. Improved diagnostic testing and guidelines could increase diagnosis rates.
Q:Will ECLIPSE-1 trial data be enough to support a BLA filing for HCV?
A:ECLIPSE-1 data alone will not be sufficient. A combination of ECLIPSE-1 and ECLIPSE-2 data will be required for filing.
Q:What is the strategy for hep B at-home self-administration?
A:The company plans to offer both at-home and in-office administration options at launch. Monthly subcutaneous administration is convenient for both settings.
Q:What is the bar for success in the Phase III ECLIPSE-1 trial for HDV?
A:The bar for success is low, as the trial compares the company's regimen to first treatment. The company's regimen has shown superior viral efficacy and ALT normalization compared to competitors.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the number of patients and tumor types for the 5818 data disclosure, as well as the exact durability threshold for 5500 in the late-line castrate-resistant setting. Additionally, they did not specify the exact framework for transitioning hep B administration from clinical to at-home settings.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Delta program
Hepatitis Delta
MCRPC
PRO XTEN
RLT
RNA
administration
capital
cash
collaboration
combination therapy
deal
disease
efficacy
expansion cohort
expense
hepatitis delta
line
monotherapy
need
offering
patient
potential
proceeds
prostate cancer
regimen
response
study
term
tobevibart elebsiran
treatment
update
virus HDV
week
VIR Transcript
Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlighted positive developments such as a strategic collaboration with Astellas and promising Phase I data for VIR-5500, which are strong catalysts. Financials showed controlled expenses and a healthy cash position, despite a slight increase in net loss. The Q&A revealed optimism in pipeline advancements and competitive positioning, despite some management evasiveness. The market cap suggests moderate sensitivity to news, supporting a positive outlook.
Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript
Unknown2-24
The earnings call summary highlights a strategic collaboration with Astellas and positive Phase I data for VIR-5500, which are positive factors. However, the financial performance shows a significant decline in revenue and net income, primarily due to reduced demand for COVID-19 treatments, which negatively impacts sentiment. The increased R&D expenses indicate ongoing investment but also contribute to lower profitability. The Q&A section lacks clarity, which doesn't help improve sentiment. Overall, the mixed signals from strategic developments and financial setbacks result in a neutral sentiment.
Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call presents a mixed picture. The company's financial health appears strong, with reduced operating expenses and a cash runway extending into 2027. However, there are concerns about the lack of specific guidance on key clinical data and the heavy reliance on strategic partnerships. While the Q&A section reveals optimism about upcoming data releases, the absence of concrete targets and timelines introduces uncertainty. The market cap suggests moderate volatility, leading to a neutral prediction for stock price movement.
VIR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
